Dr. Rémi Rabasa-Lhoret
Claim this profileInstitut de recherches cliniques de Montréal
Studies Type 1 Diabetes
Studies Hypoglycemia
7 reported clinical trials
17 drugs studied
Affiliated Hospitals
Clinical Trials Rémi Rabasa-Lhoret is currently running
Continuous Glucose Monitoring
for Cystic Fibrosis
Cystic fibrosis (CF)-related diabetes (CFRD) is the most important emerging complication after pulmonary complications. This specific form of diabetes is associated with an increased morbidity and mortality. CFRD prevalence at the age of 10 is 10% and reaches 40 to 50% in adulthood, while a similar percentage is afflicted with milder dysglycemia also called pre-diabetes abnormalities. In order to identify patients at risk and to implement early therapeutic measures, an annual CFRD screening test is recommended for CF patients after 10 years of age. The standard 2-hour oral glucose tolerance test (OGTT) is the recommended screening test. However, this test is perceived by both patients and CF care teams as unpleasant while adding a significant burden and workload, resulting in screening rates lower than 50% in most centers. An ideal alternative test should be simpler, less invasive, more sensitive than an OGTT to establish risks for lung function and/or nutritional deterioration, and predict future CFRD risk. To date, compared to the OGTT, no alternative screening method has demonstrated its effectiveness. However, continuous glucose monitoring (CGM) is emerging as a possible alternative method. In patients living with CF, CGM is easy to use and can identify early dysglycemia, which in turn, can predict increased risk of accelerated decline of pulmonary function and/or weight, higher risk of pseudomonas colonization, and future risk of CFRD. However, these observations are based on studies of small sample size with very limited prospective data. Furthermore, many of the multiple CGM metrics that have been standardized are based on the risk of complications associated with Type 1 and Type 2 Diabetes. Thus, there is a need for prospective studies to identify the CGM metrics and the cut-off level that is relevant as a predictor of clinical deterioration and/or CFRD risk in CF. The identification of such CF-specific criteria would provide important information to target at-risk patients.
Recruiting1 award N/A3 criteria
High-Intensity Exercise
for Type 1 Diabetes
The objective of this study is to investigate if the addition of a 12-week program of home-based high intensity interval training to a standard educational program aiming at preventing hypoglycemia episodes will restore hypoglycemia awareness in people living with type 1 diabetes and impaired awareness of hypoglycemia to a further extent than a standard educational program alone. Participants will be randomized for 12 weeks to the standard educational program with or without high intensity interval training. The Gold method will be used to identify people with impaired awareness of hypoglycemia. The educational program will consist of two education sessions on avoidance of hypoglycemia, causes of hypoglycemia, treatment (e.g. glucagon) of hypoglycemia, how to better recognize hypoglycemia symptoms, understand how to use a CGM/Flash-GM and understand CGM/Flash-GM reports to adjust insulin doses. Participants randomized to the training program will be asked to train three times per week for 12 weeks following the home-based program that will be provided to them. Participants will be asked to perform at least 2 training sessions per week (ideally all 3 sessions) with the exercise specialist on a virtual platform.
Recruiting1 award N/A7 criteria
More about Rémi Rabasa-Lhoret
Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Rémi Rabasa-Lhoret has experience with
- Insulin
- Home-based High Intensity Interval Training
- Physical Activity Trial Intervention
- Single-hormone Closed-loop System
- Continuous Glucose Monitoring System
- Aspart Or Lispro
Breakdown of trials Rémi Rabasa-Lhoret has run
Type 1 Diabetes
Hypoglycemia
Motor Skills
Low blood sugar awareness
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rémi Rabasa-Lhoret specialize in?
Rémi Rabasa-Lhoret focuses on Type 1 Diabetes and Hypoglycemia. In particular, much of their work with Type 1 Diabetes has involved treating patients, or patients who are undergoing treatment.
Is Rémi Rabasa-Lhoret currently recruiting for clinical trials?
Yes, Rémi Rabasa-Lhoret is currently recruiting for 3 clinical trials in Montreal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Rémi Rabasa-Lhoret has studied deeply?
Yes, Rémi Rabasa-Lhoret has studied treatments such as Insulin, Home-based High Intensity Interval Training, Physical activity trial intervention.
What is the best way to schedule an appointment with Rémi Rabasa-Lhoret?
Apply for one of the trials that Rémi Rabasa-Lhoret is conducting.
What is the office address of Rémi Rabasa-Lhoret?
The office of Rémi Rabasa-Lhoret is located at: Institut de recherches cliniques de Montréal, Montreal, Quebec H2W1R7 Canada. This is the address for their practice at the Institut de recherches cliniques de Montréal.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.